Sugi Predict

Sugi Predict / Compounds / SCHEMBL16554813

SCHEMBL16554813

SCHEMBL16554813

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COC(F)(F)F)[C@@H](O)[C@@H]1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 5/20 0.71
▸ SMN1; SMN2 Q16637 3/20 0.70
▸ ADORA3 P0DMS8 2/20 0.70
▸ ADORA2A P29274 2/20 0.70
▸ ADORA2B P29275 2/20 0.70
▸ DPP4 P27487 1/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ SLC28A1 O00337 1/20 0.70
▸ MAP3K7 O43318 1/20 0.70
▸ SLC28A2 O43868 1/20 0.70
▸ GAPDH P04406 1/20 0.70
▸ MAPK1 P28482 1/20 0.70
▸ STAT6 P42226 1/20 0.70
▸ PI4KA P42356 1/20 0.70
▸ KMT2A Q03164 1/20 0.70
▸ PI4K2B Q8TCG2 1/20 0.70
▸ DOT1L Q8TEK3 1/20 0.70
▸ SLC29A1 Q99808 1/20 0.70
▸ PI4K2A Q9BTU6 1/20 0.70
▸ SLC28A3 Q9HAS3 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7067735 1.00 ADORA1 (0.71) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL7067739 1.00 ADORA1 (0.71) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL6246363 0.88 ADORA1 (0.74) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL7732691 0.87 TYMP (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL8610903 0.87 ADORA1 (0.82) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL8610899 0.87 ADORA1 (0.82) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL31484253 0.87 ADORA1 (0.82) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL10997946 0.86 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL12963362 0.86 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL2040670 0.86 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3041843-A1 NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2016-07-13 — — EP claimed
WO-2015032769-A1 NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2015-03-12 — — WO claimed
WO-2024089633-A1 RNA MOLECULES ENCODING RSV-F AND VACCINES CONTAINING THEM PFIZER INC. (US) 2024-05-02 — — WO disclosed
EP-4324473-A2 MULTIPARAMETRIC NUCLEIC ACID OPTIMIZATION ModernaTX, Inc. (US) 2024-02-21 — — EP disclosed
US-20230346928-A1 MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER ARES CAPITAL CORPORATION, AS AGENT 2023-11-02 — — US disclosed
US-11660341-B2 mRNA combination therapy for the treatment of cancer MODERNATX, INC. (US) 2023-05-30 — — US disclosed
US-20230146324-A1 MULTIPARAMETRIC NUCLEIC ACID OPTIMIZATION MODERNATX, INC. 2023-05-11 — — US disclosed
CN-115837014-A Polynucleotides encoding relaxin 摩登纳特斯有限公司 2023-03-24 — — CN disclosed
CN-109640962-B Polynucleotides encoding relaxin 摩登纳特斯有限公司 2022-07-19 — — CN disclosed
CN-114404581-A Cancer vaccine 摩登纳特斯有限公司 2022-04-29 — — CN disclosed
CN-108430456-B Cancer vaccine 摩登纳特斯有限公司 2022-01-18 — — CN disclosed
US-20210315980-A1 TREATMENT OF FLAVIVIRUS INFECTIONS IN HUMANS USING MUS MUSCULUS RESISTANT 2'-5' OLIGOADENYLATE SYNTHETASE 1B NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-14 — — US disclosed
CN-112996854-A High purity PEG lipids and uses thereof 摩登纳特斯有限公司 2021-06-18 — — CN disclosed
US-10973917-B2 MRNA combination therapy for the treatment of cancer MODERNATX, INC. (US) 2021-04-13 — — US disclosed
US-20200054747-A1 MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER ARES CAPITAL CORPORATION, AS AGENT 2020-02-20 — — US disclosed
US-10335486-B2 MRNA combination therapy for the treatment of cancer MODERNATX, INC. (US) 2019-07-02 — — US disclosed
US-20180369374-A1 MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER ARES CAPITAL CORPORATION, AS AGENT 2018-12-27 — — US disclosed
US-20170362627-A1 MULTIPARAMETRIC NUCLEIC ACID OPTIMIZATION MODERNATX, INC. 2017-12-21 — — US disclosed
EP-3041843-A1 NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2016-07-13 — — EP disclosed
WO-2015032769-A1 NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2015-03-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10973917-B2 MRNA combination therapy for the treatment of cancer CD274, PDCD1LG2, ICOSLG ADORA1 1595/4885SMN1; SMN2 2149/4885ADORA3 320/4885
US-11660341-B2 mRNA combination therapy for the treatment of cancer CD274, PDCD1LG2, ICOSLG ADORA1 1595/4885SMN1; SMN2 2149/4885ADORA3 320/4885
US-20200054747-A1 MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER CD274, PDCD1LG2, ICOSLG ADORA1 1595/4885SMN1; SMN2 2149/4885ADORA3 320/4885
US-20180369374-A1 MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER CD274, PDCD1LG2, ICOSLG ADORA1 1595/4885SMN1; SMN2 2149/4885ADORA3 320/4885
US-10335486-B2 MRNA combination therapy for the treatment of cancer CD274, PDCD1LG2, ICOSLG ADORA1 1595/4885SMN1; SMN2 2149/4885ADORA3 320/4885
US-20230346928-A1 MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER CD274, PDCD1LG2, ICOSLG ADORA1 1595/4885SMN1; SMN2 2149/4885ADORA3 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.